Menu
No results found.
Weekly Share Price & Valuation Overview
Race Oncology Limited
Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company's lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia. In addition, it is investigating the effect of bisantrene on the m6A RNA pathway, following independent research identifying bisantrene as the potent inhibitor of fat mass and obesity-associated protein. The company has collaborations with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Coronado Resources Limited. Race Oncology Limited was incorporated in 2011 and is headquartered in Sydney, Australia.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Revenue growth ≥10% indicates solid top-line momentum.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- AUD 206.76M
- Enterprise Value Operating value: market cap + total debt − cash.
- AUD 187.94M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- AUD 5.25M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- AUD 4.11M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- AUD 0.03
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.05
- Shares Outstanding
- 173.74M
- Float Shares
- 121.18M
- Implied Shares Outstanding
- 173.74M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
3.58%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
78.13%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-1.46%
- ROA Return on assets: net income ÷ total assets.
-
-24.05%
- ROE Return on equity: net income ÷ shareholder equity.
-
-37.20%
- Revenue Growth Strong Year-over-year revenue growth.
-
31.30%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 20.39
- Total Cash Cash and equivalents.
- AUD 18.78M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- AUD -18.78M
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- AUD -820.33K
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- AUD 1.63M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-15.61%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
31.04%
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.